Every story and comment from the Hacker News API, in a layout borrowed from 2001.
A comment on Why huge gains in drug discovery tech have led to longer drug development times. Parent comment
I hadn't heard about Rexulti until today, but Abilify is heavily marketed as an adjunct therapy for treatment-resistant depression.
There are no comments on this comment yet.
I hadn't heard about Rexulti until today, but Abilify is heavily marketed as an adjunct therapy for treatment-resistant depression.